Follow
Linda Henricks
Linda Henricks
Unknown affiliation
Verified email at nki.nl
Title
Cited by
Cited by
Year
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update
U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ...
Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018
5112018
Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta …
D Meulendijks, LM Henricks, GS Sonke, MJ Deenen, TK Froehlich, ...
The Lancet Oncology 16 (16), 1639-1650, 2015
3662015
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ...
The Lancet Oncology 19 (11), 1459-1467, 2018
3272018
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
CATC Lunenburg, LM Henricks, HJ Guchelaar, JJ Swen, MJ Deenen, ...
European journal of cancer 54, 40-48, 2016
1352016
Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score
LM Henricks, CATC Lunenburg, D Meulendijks, H Gelderblom, A Cats, ...
Pharmacogenomics 16 (11), 1275-1284, 2015
1252015
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
D Meulendijks, LM Henricks, BAW Jacobs, A Aliev, MJ Deenen, ...
British Journal of Cancer 116 (11), 1415-1424, 2017
1222017
The use of combinations of monoclonal antibodies in clinical oncology
LM Henricks, JHM Schellens, ADR Huitema, JH Beijnen
Cancer treatment reviews 41 (10), 859-867, 2015
1102015
DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update
LM Henricks, FL Opdam, JH Beijnen, A Cats, JHM Schellens
Annals of Oncology 28 (12), 2915-2922, 2017
1012017
A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ...
European Journal of Cancer 107, 60-67, 2019
862019
RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
P Depeille, LM Henricks, RAH Van De Ven, E Lemmens, CY Wang, ...
Nature cell biology 17 (6), 804-815, 2015
672015
Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma
BAW Jacobs, H Rosing, N de Vries, D Meulendijks, LM Henricks, ...
Journal of Pharmaceutical and Biomedical Analysis 126, 75-82, 2016
522016
Individualized dosing of fluoropyrimidine‐based chemotherapy to prevent severe fluoropyrimidine‐related toxicity: what are the options?
JE Knikman, H Gelderblom, JH Beijnen, A Cats, HJ Guchelaar, ...
Clinical Pharmacology & Therapeutics 109 (3), 591-604, 2021
502021
Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis
LM Henricks, LN van Merendonk, D Meulendijks, MJ Deenen, JH Beijnen, ...
International Journal of Cancer 144 (9), 2347-2354, 2019
482019
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity
D Meulendijks, LM Henricks, U Amstutz, TK Froehlich, CR Largiadèr, ...
International journal of cancer 138 (11), 2752-2761, 2016
422016
Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
LM Henricks, BAW Jacobs, D Meulendijks, D Pluim, D van den Broek, ...
British Journal of Clinical Pharmacology 84 (12), 2761-2769, 2018
332018
Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study
M de With, J Knikman, FM de Man, CATC Lunenburg, LM Henricks, ...
Clinical Pharmacology & Therapeutics 112 (1), 62-68, 2022
292022
guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update
U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ...
Clin Pharmacol Ther 103 (2), 210-6, 2018
252018
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines
D Meulendijks, LM Henricks, ABP van Kuilenburg, BAW Jacobs, A Aliev, ...
Cancer chemotherapy and pharmacology 78, 875-880, 2016
232016
Capecitabine‐based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency
LM Henricks, EJM Siemerink, H Rosing, J Meijer, SMI Goorden, ...
International journal of cancer 142 (2), 424-430, 2018
212018
Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine.
LM Henricks, E Kienhuis, FM de Man, AAM van der Veldt, P Hamberg, ...
JCO Precision Oncology 1, 1-10, 2017
212017
The system can't perform the operation now. Try again later.
Articles 1–20